Clinical Trials List
Protocol NumberBGB-A317-Sitravatinib-303
2022-09-15 - 2023-04-25
Phase III
Terminated1
ICD-10C22.9
Malignant neoplasm of liver, not specified as primary or secondary
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9155.2
Malignant neoplasm of liver, not specified as primary or secondary
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2025/08/20
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
90 participants
-
Global
832 participants
